Inventors: Wafaa BeedAllah Hameedi Al- Rekaby/Minstry of education, Di Qar, Iraq
Assist. Prof. Dr. Muna Turkey Mossa Al- Mossawei/Department of biology, College of science, University of Baghdad
Mohammad Ismael Majeed/Minstry of health
Abstract
Typhoid fever, which is caused by Salmonella enterica subspeciesenterica serovar Typhi (S. Typhi) is an exclusively human entericallytransmitted, range from mild gastroenteritis to severe systemic diseaseand spread by the fecal-oral route via contaminated food and water. In this study aimed to production vaccine against typhoid fever fromlocal strain S. Typhi and comparative with Vi polysaccharide (commercial) that prepared from standard strain bacteria according toprotocol WHO. The local strain of S. Typhi was obtained from blood Iraqi patient /The National Center of Drugs Control and Research (NCDCR) / IraqiMinistry of Health. All confirmed the identity of the bacteria belongingto S. Typhi. Good quality and efficacy was obtained in the locally produced vaccinefrom the biological, chemical, physical and Immunological comparedwith the imported commercial vaccine. That a result of chemical test (phenol and formalin residuals) by High- Performance LiquidChromatography (HPLC) and Gas Chromatography (GC), PH value were safety side comparative with WHO protocol typhoid vaccine. Also inphysical test, the particles size of local PS vaccine was less than Com. Vi, the smaller of particles size of vaccine supports the immune response. In immunologicaltest by Enzyme Linked Immunsorbent Assay(ELISA) was showed that the titration of all vaccines and havesignificantly differences (P<0.05) in the sera of treated guinea pigsbetween first and booster dose compared withcontrol. The Commercialand local Vi PS but all of them provided (70 and 80) % protectionrespectively against virulent S. Typhi organism. The prepared vaccinesmay be able to enhance the adaptive immunity through its recordedsignificant different (P<0.05) in the total leukocytes count between firstand booster dose compared with the Commercial Vaccine and controlgroups. The study recommends to developing production of Iraqi ViPolysaccharide. Typhoid vaccine from this local virulent strain of S.Typhi.